We are live on ! Find out more
NVS icon

Novartis

1,177 hedge funds and large institutions have $21.5B invested in Novartis in 2020 Q4 according to their latest regulatory filings, with 146 funds opening new positions, 379 increasing their positions, 437 reducing their positions, and 71 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more call options, than puts

Call options by funds: $245M | Put options by funds: $117M

106% more first-time investments, than exits

New positions opened: 146 | Existing positions closed: 71

9% more capital invested

Capital invested by funds: $19.7B → $21.5B (+$1.86B)

8% more funds holding in top 10

Funds holding in top 10: 1314 (+1)

5% more funds holding

Funds holding: 1,1191,177 (+58)

0.07% more ownership

Funds ownership: 9.17%9.24% (+0.07%)

13% less repeat investments, than reductions

Existing positions increased: 379 | Existing positions reduced: 437

Holders
1,177
Holders Change
+58
Holders Change %
+5.18%
% of All Funds
20.82%
Holding in Top 10
14
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.69%
% of All Funds
0.25%
New
146
Increased
379
Reduced
437
Closed
71
Calls
$245M
Puts
$117M
Net Calls
+$128M
Net Calls Change
+$74.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$154M -$9.44M -108,059 -6%
ClearBridge Investments
27
ClearBridge Investments
New York
$149M +$690K +7,893 +0.5%
Lazard Asset Management
28
Lazard Asset Management
New York
$141M -$32.8M -374,806 -20%
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$137M -$7.36M -84,276 -5%
Neuberger Berman Group
30
Neuberger Berman Group
New York
$137M -$65.5M -749,624 -34%
Fidelity Investments
31
Fidelity Investments
Massachusetts
$124M +$10.5M +120,181 +10%
Natixis Advisors
32
Natixis Advisors
Massachusetts
$123M +$18.8M +215,686 +20%
RJA
33
Raymond James & Associates
Florida
$116M +$5.7M +65,283 +6%
SI
34
Scharf Investments
California
$113M -$1.29M -14,815 -1%
AG
35
Aperio Group
California
$112M +$5.43M +62,090 +6%
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$109M -$8.45M -96,746 -8%
EARNEST Partners
37
EARNEST Partners
Georgia
$93.7M +$1.81M +20,661 +2%
Invesco
38
Invesco
Georgia
$92.2M -$51.6M -590,111 -38%
Truist Financial
39
Truist Financial
North Carolina
$84.3M +$4.79M +54,765 +7%
MAM
40
Madison Asset Management
Wisconsin
$83.3M +$2.96M +33,915 +4%
Envestnet Asset Management
41
Envestnet Asset Management
Illinois
$81.4M +$2.06M +23,536 +3%
Chevy Chase Trust
42
Chevy Chase Trust
Maryland
$79.2M -$1.43M -16,328 -2%
SEI Investments
43
SEI Investments
Pennsylvania
$74.4M -$666K -7,618 -1%
JWBC
44
John W. Bristol & Co
New York
$71.3M -$95.9K -1,097 -0.1%
BlackRock
45
BlackRock
New York
$65.4M -$24.9M -284,823 -29%
DLA
46
Douglas Lane & Associates
New York
$59.8M +$4.93M +56,433 +10%
Bank of New York Mellon
47
Bank of New York Mellon
New York
$58.1M -$1.48M -16,924 -3%
First Trust Advisors
48
First Trust Advisors
Illinois
$57.4M +$1.94M +22,184 +4%
Macquarie Group
49
Macquarie Group
Australia
$57.2M -$2.12M -24,286 -4%
CCM
50
Cullen Capital Management
New York
$49.6M -$10.5M -119,909 -19%

NVS Hedge Fund Activity: Q4 2020 in Review

1,177 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2020, worth a combined $21.5B — up 9.5% from $19.7B a quarter earlier.

Buyers outnumbered sellers: 146 funds opened new NVS positions and 71 closed out — a net gain of 75 holders — while 379 added to existing stakes and 437 trimmed.

The largest buyer was Loomis, Sayles & Company, adding an estimated $840M. The largest seller was Renaissance Technologies, cutting an estimated $168M.

  • 1,177 institutional investors held Novartis (NVS) as of Q4 2020, up from 1,119 in Q3 2020.
  • Funds reported $21.5B of Novartis stock for Q4 2020, up 9.5% quarter-over-quarter.
  • 146 funds opened new Novartis positions in Q4 2020 and 71 closed out, a net change of +75 holders.
  • The largest Novartis buyer in Q4 2020 was Loomis, Sayles & Company, an estimated $840M added.
  • The largest Novartis seller in Q4 2020 was Renaissance Technologies, an estimated $168M sold.

Based on aggregated 13F filings for Q4 2020.